Letting go.

As oncology therapies evolve, there are more and more opportunities for patients with metastatic disease to benefit from radiation. But the calculus continues to balance the benefit with additional toxicity and time. This article brings that thought process to post-radiation follow-up. On the one hand, there’s certainly utility in rad oncs being kept in the loop of how patients are doing to ensure timely access for further palliative radiation, particularly in light of data suggesting many meds onc feel their rad onc colleagues have no role in end-of-life care. On the other hand, there’s no clear benefit of surveillance imaging and routine follow-up to screen for asymptomatic mets in most patients. At the end of the day, guidelines may not be helpful for such a heterogeneous population, but it’s worth considering if that reflex post-treatment appointment is really necessary, especially if travel and/or scans are involved. | Tringale, APM 2021


Popular Posts